CN100343252C - 具有治疗作用的新咪唑并吡啶化合物 - Google Patents

具有治疗作用的新咪唑并吡啶化合物 Download PDF

Info

Publication number
CN100343252C
CN100343252C CNB028160177A CN02816017A CN100343252C CN 100343252 C CN100343252 C CN 100343252C CN B028160177 A CNB028160177 A CN B028160177A CN 02816017 A CN02816017 A CN 02816017A CN 100343252 C CN100343252 C CN 100343252C
Authority
CN
China
Prior art keywords
alkyl
compound
formula
het
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028160177A
Other languages
English (en)
Chinese (zh)
Other versions
CN1543464A (zh
Inventor
K·阿明
M·达尔斯特伦
P·诺尔德贝里
I·施塔克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1543464A publication Critical patent/CN1543464A/zh
Application granted granted Critical
Publication of CN100343252C publication Critical patent/CN100343252C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB028160177A 2001-08-22 2002-08-21 具有治疗作用的新咪唑并吡啶化合物 Expired - Fee Related CN100343252C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE01028083 2001-08-22
SE0102808A SE0102808D0 (sv) 2001-08-22 2001-08-22 New compounds

Publications (2)

Publication Number Publication Date
CN1543464A CN1543464A (zh) 2004-11-03
CN100343252C true CN100343252C (zh) 2007-10-17

Family

ID=20285105

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028160177A Expired - Fee Related CN100343252C (zh) 2001-08-22 2002-08-21 具有治疗作用的新咪唑并吡啶化合物

Country Status (19)

Country Link
US (1) US20040220209A1 (enExample)
EP (1) EP1421083A1 (enExample)
JP (1) JP2005501870A (enExample)
KR (1) KR20040036723A (enExample)
CN (1) CN100343252C (enExample)
AR (1) AR035465A1 (enExample)
BR (1) BR0211846A (enExample)
CA (1) CA2456350A1 (enExample)
HU (1) HUP0401350A3 (enExample)
IL (1) IL160143A0 (enExample)
IS (1) IS7159A (enExample)
MX (1) MXPA04001402A (enExample)
NO (1) NO20040760L (enExample)
NZ (1) NZ531110A (enExample)
PL (1) PL367971A1 (enExample)
RU (1) RU2294935C2 (enExample)
SE (1) SE0102808D0 (enExample)
WO (1) WO2003018582A1 (enExample)
ZA (1) ZA200401114B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301904D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab Novel imidazopyridine compound II with therapeutic effect
EP1974730A1 (en) 2003-11-03 2008-10-01 AstraZeneca AB Imidazo[1,2-a]pyridine derivatives for use in the treatment of sleep disturbance due to silent gastro-esophageal reflux
EP1711498A2 (en) * 2004-01-26 2006-10-18 Altana Pharma AG 1,2,4-triazolo¬1,5-a|pyridines as gastric acid secretion inhibitors
EA011512B1 (ru) * 2004-12-17 2009-04-28 Ракуалиа Фарма Инк. Производные хромана, полезные в качестве антагонистов кислотной помпы
GB0513423D0 (en) * 2005-06-30 2005-08-03 Glaxo Group Ltd Novel compounds
CA2645007A1 (en) * 2006-03-17 2007-09-27 Raqualia Pharma Inc. Chromane derivatives
WO2008059373A1 (en) * 2006-11-17 2008-05-22 Raqualia Pharma Inc. Imidazo [1, 2-a] pyrazine derivatives and their use as acid pump antagonists
KR200449743Y1 (ko) * 2008-03-11 2010-08-05 주식회사 보루네오가구 파티션용 상부 스크린의 고정구조
FI20086158A0 (fi) 2008-12-03 2008-12-03 Mikael Dahlstroem Imidatsopyridiinijohdannaiset
JP5802898B2 (ja) 2009-07-09 2015-11-04 ラクオリア創薬株式会社 消化管運動異常が関与する疾患を治療するためのアシッドポンプ拮抗剤
DK2480546T3 (en) * 2009-09-24 2015-02-02 Hoffmann La Roche Imidazopyridine or imidazopyrimidinderivater as phosphodiesterase inhibitors 10A
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
KR102120513B1 (ko) * 2013-01-31 2020-06-08 네오메드 인스티튜트 이미다조피리딘 화합물 및 이의 용도
CA2909477A1 (en) * 2013-04-30 2014-11-06 F. Hoffmann-La Roche Ag Pd-catalyzed coupling of pyrazole amides
CN106279151A (zh) * 2015-06-26 2017-01-04 江苏太瑞生诺生物医药科技有限公司 5-(2-(8-((2,6-二甲基苄基)氨基)-2,3-二甲基咪唑并[1,2-a]吡啶-6-甲酰胺基)乙氧基)-5-氧代戊酸的固体形式及其制备方法
EP3930722A4 (en) 2019-02-25 2022-12-28 Bellus Health Cough Inc. TREATMENT WITH P2X3 MODULATORS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055706A1 (en) * 1998-04-29 1999-11-04 Astrazeneca Ab Imidazo pyridine derivatives which inhibit gastric acid secretion

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA81219B (en) * 1980-01-23 1982-01-27 Schering Corp Imidazo (1,2-a) pyridines ,process for their preparation and pharmaceutical compositions containing them
DE3269604D1 (en) * 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
US4725601A (en) * 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
EP0228006A1 (en) * 1985-12-16 1987-07-08 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
IL108520A (en) * 1993-02-15 1997-09-30 Byk Gulden Lomberg Chem Fab 2, 3, 8-TRISUBSTITUTED IMIDAZO £1, 2-a| PYRIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UA48122C2 (uk) * 1993-10-11 2002-08-15 Бік Гульден Ломберг Хеміше Фабрік Гмбх АЛКОКСІАЛКІЛКАРБАМАТИ ІМІДАЗО[1,2-а]ПІРИДИНІВ, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ЛІКАРСЬКИЙ ЗАСІБ НА ЇХ ОСНОВІ
PL180278B1 (pl) * 1994-07-28 2001-01-31 Byk Gulden Lomberg Chem Fab Nowe imidazopirydyno-azolidynony, sposób ich wytwarzania oraz srodek farmaceutyczny PL PL PL PL PL PL PL
SE9802794D0 (sv) * 1998-08-21 1998-08-21 Astra Ab New compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055706A1 (en) * 1998-04-29 1999-11-04 Astrazeneca Ab Imidazo pyridine derivatives which inhibit gastric acid secretion

Also Published As

Publication number Publication date
RU2294935C2 (ru) 2007-03-10
BR0211846A (pt) 2004-09-08
PL367971A1 (en) 2005-03-07
JP2005501870A (ja) 2005-01-20
MXPA04001402A (es) 2004-05-27
EP1421083A1 (en) 2004-05-26
NO20040760L (no) 2004-02-20
WO2003018582A1 (en) 2003-03-06
IS7159A (is) 2004-02-20
HUP0401350A3 (en) 2009-03-02
NZ531110A (en) 2005-10-28
US20040220209A1 (en) 2004-11-04
KR20040036723A (ko) 2004-04-30
ZA200401114B (en) 2005-06-22
IL160143A0 (en) 2004-06-20
AR035465A1 (es) 2004-05-26
SE0102808D0 (sv) 2001-08-22
CA2456350A1 (en) 2003-03-06
HUP0401350A2 (hu) 2004-12-28
RU2004103628A (ru) 2005-06-27
CN1543464A (zh) 2004-11-03

Similar Documents

Publication Publication Date Title
CN1100056C (zh) 抑制胃酸分泌的化合物
CN1306533A (zh) 抑制胃酸分泌的咪唑并吡啶衍生物
CN100343252C (zh) 具有治疗作用的新咪唑并吡啶化合物
CN1142933C (zh) 抑制胃酸分泌的杂环化合物、其制备方法及其药物组合物
CN1093707A (zh) 亚乙烯基氮杂吲哚衍生物及其制备方法
CN1043713A (zh) 新的治疗活性化合物及其制备方法
CN1161355C (zh) 新的化合物
CN1280292C (zh) 用作磷酸二酯酶抑制剂的被取代的四环吡咯并喹诺酮衍生物
CN1101385C (zh) 取代的苯并咪唑衍生物及其制法和药物用途
CN1329613A (zh) 新的化合物
CN1171589C (zh) 脲酶抑制剂
CN1610683A (zh) 作为磷酸酶抑制剂的嘧啶并三嗪
CN1942437A (zh) 作为环氧化酶－1－环氧化酶－2抑制剂的取代氮杂环丁烷化合物及其制备方法和作为药物的用途
CN1309642A (zh) 具有止喘、抗变态反应、抗炎、免疫调节和神经保护作用的新的1,2,5－三取代1,2－二氢吲唑－3－酮类化合物、其制备方法以及作为药物的应用
CN1137793A (zh) 用作α2肾上腺素能受体兴奋剂的6-(2-咪唑啉基氨基)喹啉化合物
CN1258277A (zh) 细胞增生抑制剂氰基胍
CN1092074A (zh) 二氮杂䓬衍生物
CN1159806A (zh) 咪唑并吡啶-吡咯烷酮和咪唑并吡啶-噁唑烷酮
CN1183115C (zh) 5-氨基-8-甲氧基喹诺酮羧酸类衍生物及其制法
CN1073446A (zh) 取代的苯并咪唑及其制备工艺和用途
CN1610679A (zh) 制备因子xa抑制剂的有效方法
CN1563004A (zh) 喹诺酮羧酸类化合物及其制备方法和医药用途
CN1726215A (zh) 作为pde4抑制剂的[1,7]二氮杂萘
CN1370172A (zh) 光学活性的吡咯并哒嗪化合物
CN1479619A (zh) 吡唑并[4,3-d]嘧啶类化合物的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee